[Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis]

Nihon Shokakibyo Gakkai Zasshi. 2015 Feb;112(2):287-96. doi: 10.11405/nisshoshi.112.287.
[Article in Japanese]

Abstract

Systemic chemotherapy based on 5-fluorouracil (5-FU) is a standard treatment for unresectable or recurrent large intestinal cancer. Although hyperammonemia is a known side effect of 5-FU that can cause serious pathological conditions, only a few cases have been reported. We describe 4 cases of 5-FU-related hyperammonemia with impairment of consciousness in patients who received 5-FU chemotherapy for large intestinal cancer with multiple liver metastases. Hemodialysis was effective in 1 severe case. There have been no detailed reports on the use of hemodialysis for hyperammonemia caused by 5-FU. Renal dysfunction is considered to be a risk factor for hyperammonemia caused by 5-FU and it is necessary to pay particular attention in patients with renal dysfunction who receive chemotherapy with 5-FU. Here we summarize our cases together with 16 previously reported cases of hyperammonemia caused by 5-FU in Japan.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / adverse effects*
  • Fluorouracil / adverse effects*
  • Humans
  • Hyperammonemia / chemically induced*
  • Hyperammonemia / therapy
  • Intestinal Neoplasms / drug therapy*
  • Intestinal Neoplasms / pathology
  • Intestine, Large*
  • Liver Neoplasms / secondary*
  • Male
  • Middle Aged
  • Renal Dialysis

Substances

  • Antimetabolites, Antineoplastic
  • Fluorouracil